{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:26:34Z","timestamp":1781781994945,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26317-1","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T19:22:35Z","timestamp":1765308155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Correlation analysis between RAS gene mutations and pathological morphological features in colorectal cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Lili","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"6","key":"26317_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/PAI.0000000000001137","volume":"31","author":"D Sun","year":"2023","unstructured":"Sun, D., Liu, Y., Li, P., Yang, P. & Yu, G. Clinicopathological features and prognosis of lung adenocarcinoma patients with K-RAS gene mutation. Appl. Immunohistochem. Mol. Morphol. 31 (6), 406\u2013413 (2023).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"12","key":"26317_CR2","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1158\/1078-0432.CCR-21-4391","volume":"28","author":"S Fujii","year":"2022","unstructured":"Fujii, S. et al. Rapid screening using pathomorphologic interpretation to detect BRAF V600E mutation and microsatellite instability in colorectal cancer. Clin. Cancer Res. 28 (12), 2623\u20132632 (2022).","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"26317_CR3","doi-asserted-by":"publisher","first-page":"13617","DOI":"10.3390\/cimb46120814","volume":"46","author":"B Ochman","year":"2024","unstructured":"Ochman, B. et al. Association of SIGLEC9 expression with cytokine expression, tumor grading, KRAS, NRAS, BRAF, PIK3CA, AKT gene mutations, and MSI status in colorectal cancer. Curr. Issues Mol. Biol. 46 (12), 13617\u201313646 (2024).","journal-title":"Curr. Issues Mol. Biol."},{"issue":"2","key":"26317_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5114\/pjp.2024.139935","volume":"75","author":"P Poter","year":"2024","unstructured":"Poter, P. et al. Association of PD-1 and PD-L1 protein expression with selected clinical and morphological parameters in colorectal cancers. Pol. J. Pathol. 75 (2), 105\u2013114 (2024).","journal-title":"Pol. J. Pathol."},{"issue":"1","key":"26317_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.17816\/KMJ101454","volume":"106","author":"YR Aliyarov","year":"2025","unstructured":"Aliyarov, Y. R. The role of KRAS and BRAF gene mutations as predictive factors in the treatment of locally advanced rectal cancer. Kazan Med. J. 106 (1), 98\u2013104 (2025).","journal-title":"Kazan Med. J."},{"issue":"3","key":"26317_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/cancers17030428","volume":"17","author":"M Takeda","year":"2025","unstructured":"Takeda, M. et al. The role of KRAS mutations in colorectal cancer: biological insights, clinical implications, and future therapeutic perspectives. Cancers 17 (3), 428 (2025).","journal-title":"Cancers"},{"issue":"11","key":"26317_CR7","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1158\/2159-8290.CD-24-0206","volume":"14","author":"T Hashimoto","year":"2024","unstructured":"Hashimoto, T. et al. The SCRUM-MONSTAR cancer-omics ecosystem: striving for a quantum leap in precision medicine. Cancer Discov. 14 (11), 2243\u20132261 (2024).","journal-title":"Cancer Discov"},{"issue":"4","key":"26317_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.20538\/1682-0363-2023-4-57-64","volume":"22","author":"SS Naumov","year":"2024","unstructured":"Naumov, S. S. et al. Clinicopathological features of colon cancer depending on the dMMR status of the tumor. Bull. Sib Med. 22 (4), 57\u201364 (2024).","journal-title":"Bull. Sib Med."},{"issue":"12","key":"26317_CR9","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1111\/bph.15420","volume":"179","author":"FM Healy","year":"2022","unstructured":"Healy, F. M., Prior, I. A. & MacEwan, D. J. The importance of Ras in drug resistance in cancer. Br. J. Pharmacol. 179 (12), 2844\u20132867 (2022).","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"26317_CR10","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ymthe.2023.03.017","volume":"31","author":"TE Escher","year":"2023","unstructured":"Escher, T. E. & Satchell, K. J. RAS degraders: the new frontier for RAS-driven cancers. Mol. Ther. 31 (7), 1904\u20131919 (2023).","journal-title":"Mol. Ther."},{"issue":"10","key":"26317_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar, S. R., Velcheti, V., Neel, B. G. & Wong, K. K. The current state of the Art and future trends in RAS-targeted cancer therapies. Nat. Rev. Clin. Oncol. 19 (10), 637\u2013655 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"26317_CR12","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 75 (1), 10 (2025).","journal-title":"CA Cancer J. Clin."},{"issue":"7900","key":"26317_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41586-022-04451-4","volume":"603","author":"Y Kobayashi","year":"2022","unstructured":"Kobayashi, Y. et al. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature 603 (7900), 335\u2013342 (2022).","journal-title":"Nature"},{"issue":"9","key":"26317_CR14","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/1346-8138.16822","volume":"50","author":"H Ono","year":"2023","unstructured":"Ono, H. et al. Schimmelpenning-Feuerstein-Mims syndrome induced by HRAS Gly12Ser somatic mosaic mutation: case report and literature review. J. Dermatol. 50 (9), 1213\u20131215 (2023).","journal-title":"J. Dermatol."},{"issue":"6","key":"26317_CR15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger, R. et al. Efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated metastatic colorectal cancer. Cancer Discov. 14 (6), 982\u2013993 (2024).","journal-title":"Cancer Discov"},{"issue":"2","key":"26317_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","volume":"11","author":"T Isermann","year":"2025","unstructured":"Isermann, T., Sers, C., Der, C. J. & Papke, B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer. 11 (2), 91\u2013116 (2025).","journal-title":"Trends Cancer"},{"issue":"4","key":"26317_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/2159-8290.CD-22-0035","volume":"12","author":"C Johnson","year":"2022","unstructured":"Johnson, C., Burkhart, D. L. & Haigis, K. M. Classification of KRAS-activating mutations and the implications for therapeutic intervention. Cancer Discov. 12 (4), 913\u2013923 (2022).","journal-title":"Cancer Discov"},{"issue":"7","key":"26317_CR18","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","volume":"13","author":"MV Negrao","year":"2023","unstructured":"Negrao, M. V. et al. Comutations and KRASG12C inhibitor efficacy in advanced NSCLC. Cancer Discov. 13 (7), 1556\u20131571 (2023).","journal-title":"Cancer Discov"},{"issue":"6","key":"26317_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/17568919.2025.2476387","volume":"17","author":"Z Ge","year":"2025","unstructured":"Ge, Z. et al. Recent advances in targeted degradation in the RAS pathway. Future Med. Chem. 17 (6), 693\u2013708 (2025).","journal-title":"Future Med. Chem."},{"issue":"4","key":"26317_CR20","first-page":"694","volume":"61","author":"N Ilhan","year":"2025","unstructured":"Ilhan, N. et al. Regional and gender-based distribution of KRAS mutations in metastatic colorectal cancer patients in Turkey: an observational study. Med. (Kaunas). 61 (4), 694 (2025).","journal-title":"Med. (Kaunas)"},{"issue":"23","key":"26317_CR21","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl. J. Med. 389 (23), 2125\u20132139 (2023).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"26317_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40291-021-00564-0","volume":"26","author":"T Krishnan","year":"2022","unstructured":"Krishnan, T., Roberts-Thomson, R., Broadbridge, V. & Price, T. Targeting mutated KRAS genes to treat solid tumours. Mol. Diagn. Ther. 26 (1), 39\u201349 (2022).","journal-title":"Mol. Diagn. Ther."},{"issue":"8","key":"26317_CR23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher, A. et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl. J. Med. 389 (8), 710\u2013721 (2023).","journal-title":"N Engl. J. Med."}],"updated-by":[{"DOI":"10.1038\/s41598-026-36079-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26317-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26317-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26317-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:11:14Z","timestamp":1768392674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26317-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26317"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26317-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-36079-z","URL":"https:\/\/doi.org\/10.1038\/s41598-026-36079-z","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43515"}}